Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a ‘diSArm’ Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

/in

Initiation of the Phase 2a portion follows DRC review of positive safety and tolerability data from recently completed Phase 1b portion Study being conducted in partnership with the U.S. Department of Defense LOS ANGELES, Sept. 26, 2023 /Link here/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for […]

Read more

CalciMedica Announces Upcoming Presentations and Events in September

/in

LA JOLLA, Calif., Sept. 6, 2023 /Link here/ — CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a presentation at the H.C. Wainwright 25th […]

Read more

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

/in

LA JOLLA, Calif., Aug. 31, 2023 /PRNewswire/ Link here — CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a virtual clinical experts event on Thursday, September 21, 2023, from 10:30 […]

Read more